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Abstract
Background: Granzyme B, one of the most abundant gran-
zymes in cytotoxic T-lymphocyte (CTL) granules, and mem-
bers of the caspase (cysteine aspartyl proteinases) family have
a unique cleavage specificity for aspartic acid in P1 and play
critical roles in the biochemical events that culminate in cell
death.
Results : We have determined the three-dimensional structure of
the complex of the human granzyme B with a potent tetrapeptide
aldehyde inhibitor. The Asp-specific S1 subsite of human
granzyme B is significantly larger and less charged than the
corresponding Asp-specific site in the apoptosis-promoting
caspases, and also larger than the corresponding subsite in rat
granzyme B.
Conclusions: The above differences account for the variation in
substrate specificity among granzyme B, other serine proteases
and the caspases, and enable the design of specific inhibitors that
can probe the physiological functions of these proteins and the
disease states with which they are associated. ß 2001 Published
by Elsevier Science Ltd.
Keywords: Autoimmunity; Cell death; Crystal structure; Drug design;
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1. Introduction
Cytotoxic lymphocytes (CLs) are important mediators
of cell-mediated immunity, where they are responsible for
the destruction of virally infected and transformed cells via
two distinct apoptotic mechanisms [1,2]. One involves li-
gation of Fas ligand to its receptor on target cells, which
results in engagement of an apoptotic cascade mediated by
members of the caspase family of cysteine proteases. An
alternate pathway involves granzymes, a family of serine
proteases contained within the cytoplasmic granules of
CLs, and the pore-forming protein, perforin. According
to the current model for granule-mediated apoptosis, kill-
ing involves degranulation and subsequent transfer of
these proteases into the cytoplasm of the target cell, where
they rapidly induce apoptosis [3]. Several lines of evidence
suggest that granzyme B is the predominant protease in-
volved in this latter pathway. First and most compelling,
CLs from granzyme B-de¢cient mice do not e⁄ciently kill
target cells [4]. Second, granzyme B and perforin alone can
induce apoptosis in target cells [5]. Finally, granzyme B is
the most abundant protease contained within cytoplasmic
granules [6,7]. Granzyme B-induced cell death appears to
be mediated primarily via activation of caspases [8,9].
However, there is mounting evidence that granzyme B
can also kill cells via a caspase-independent pathway
[10,11]. Indeed, this serine protease and the caspases ap-
pear to cleave some of the same cellular substrates, result-
ing in the demise of the cells [11,12]. This mechanism has
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presumably evolved to facilitate killing of cells infected
with viruses that encode caspase inhibitors.
Granzyme B and the caspase family members are the
only proteases that have been unequivocally established to
be involved in cell death. Despite their distinct catalytic
mechanisms, they share a novel and stringent speci¢city
for aspartic acid in the P1 position [13,14]. The granzyme
B optimal tetrapeptide recognition motif (P4^P1), IEPD,
is also similar to that of caspases involved in the initiation
of apoptosis (caspase-8, caspase-9), presumably re£ecting
their common role in the activation of downstream cas-
pases such as caspase-3, which is activated via cleavage at
an IETD site [14,15]. In contrast to these similarities, there
are also striking di¡erences in the substrate recognition
properties of these enzymes. For example, caspases cleave
tetrapeptides and macromolecules with comparable, high
e⁄ciency [15]. Conversely, granzyme B cleaves tetrapep-
tide substrates poorly relative to macromolecules, indicat-
ing that substrate recognition involves features beyond the
(P4^P1) IEPD recognition motif [14,16]. In addition, pro-
apoptotic substrates that are common to the caspases and
granzyme B are cleaved e⁄ciently by both, but at distinct
sites [11]. The crystal structures of several caspases have
been determined and provide a rationale for the substrate
speci¢cities of these enzymes [17^22]. To understand the
structural basis for the similarities and di¡erences in the
substrate recognition properties of the caspases and gran-
zyme B, we have determined the three-dimensional crystal
structure of human granzyme B. This information may
facilitate e¡orts to design selective inhibitors that can be
used to further probe the distinct biological roles of these
enzymes, and to explore their potential value as therapeu-
tic targets.
2. Results and discussion
2.1. Granzyme B structure
We solved the three-dimensional structure of granzyme
B in complex with the tetrapeptide aldehyde inhibitor Ac-
IEPD-CHO at a nominal resolution of 2.0 Aî . A model
based on cathepsin G [23], a serine protease with a 56%
identity and a 67% similarity to the amino acid sequence
of granzyme B, was used to solve the structure of gran-
zyme B by molecular replacement. Analogous to other
serine proteases [14,23^26], the granzyme B structure is
folded into two six-stranded L-barrels, which are con-
nected by three trans-domain segments. Other regular sec-
ondary structure elements include a helical loop between
Ala 56 and Cys 58, a helix involving residues from Asp
165 to Leu 172, and a long C-terminal helix from Phe 234
to Arg 244 (see Fig. 1). The peptide group between Pro
224 and Pro 225 is in the cis conformation in granzyme B
as well as in cathepsin G [23], rat mast cell protease II [27],
and human chymase [25]. The cis proline conformation in
human granzyme B orients the positively charged arginine
side chain of amino acid 226 into the S1 subsite to interact
optimally with the negatively charged P1 aspartic acid of
the inhibitor. The above Pro 224^Pro 225 pair is part of a
shortened segment, Xaa 221^Xaa 224^Pro 225 (residues
222 and 223 are missing), that is common for this subfam-
ily [28] of serine proteases. In the longer segments of hu-
man leukocyte elastase, bovine chymotrypsinogen and bo-
vine L-trypsin, Pro 225 is in the typical trans conformation
when residue 224 is not a proline [23]. Using the human
granzyme B sequence as a query, a computer search was
conducted against sequences available in public databases.
Of the top 500 protease sequences resulting from this
query, the Xaa 221^Xaa 224^Pro 225^Arg 226 motif
(based on homology modeling) was only found in human,
mouse and rat granzyme B, rat granzyme J (rat natural
killer protease-5, RNKP-5), mouse and rat mast cell pro-
tease-8 (MMCP-8 and RMCP-8) and rat mast cell pro-
tease-9 (RMCP-9). As shown in Table 1, human and
mouse granzyme B have the Xaa 221^Pro 224^Pro 225^
Arg 226 motif and have a P1 speci¢city for aspartic acid.
Interestingly, rat granzyme B with a Xaa 221^Thr 224^Pro
225^Arg 226 motif also has P1 Asp speci¢city [14], imply-
ing that Pro 225 is in the cis conformation in the short-
ened loop. The recently published structure of rat gran-
zyme B also contains the cis conformation of Pro 225 in
the shortened loop [29]. Granzyme J, MMCP-8, RMCP-8,
and RMCP-9 also have the Xaa 221^Xaa 224^Pro 225^
Arg 226 motif but residue 216, which is typically a glycine
forming two of the three anti-parallel L-structure-like hy-
Fig. 1. (A) Ribbon plot of human granzyme B. The view (referred to as standard orientation) is towards the active site cleft, which runs left to right
across the molecular surface. The Ac-IEPD-CHO inhibitor is depicted as a red ball-and-stick model. (B) Stereoview of optimal superposition of the CK-
structures of granzyme B (green, the bound structure of Ac-IEPD-CHO is in gold) and cathepsin G (silver). The view is the standard view as in (A).
Landmark residues are identi¢ed by amino acid sequence numbers. (C) The amino acid sequences of human granzyme B and human cathepsin G
aligned by matching residues that have similar secondary structures or conformation in the aligned three-dimensional structures of the two proteins.
Residues in helices are beneath the cyan rectangles; L-strands, red rectangles. Lowercase letters represent residues for which no electron density is evi-
dent. To facilitate comparison between granzyme B and cathepsin G, the amino acid residues of granzyme B are identi¢ed by the sequence numbers of
the homologous residues in cathepsin G in this alignment. The numbering scheme for this family of serine proteases is traditionally based on the zymo-
gen, chymotrypsinogen. (Activation of granzyme B involves several proteolytic cleavages generating an active protease containing a new N-terminal Ile
16.) Granzyme B sequence-speci¢c insertions are indicated by the additions of letters to the cathepsin G sequence numbers. Asterisks indicate the 220
residue CK’s with similar conformations that were used to align the structures. The poorly de¢ned loop (Asp 36A, Gln 36B, Lys 37 and Ser 38), the
two granzyme B-speci¢c insertions (Pro 145A and Arg 172A) and Tyr 245 (no electron density) were excluded from the alignment.
C
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drogen bonds between the inhibitor backbone and the
enzyme (see Fig. 2), is an arginine. This large, positively
charged side chain will point right into the S1 subsite
causing the side chain of Arg 226 to most likely displace
the water molecules from the extended area of the S1
subsite (see Fig. 3). Similar to the caspases (Fig. 2), the
S1 subsite with two arginines, including granzyme J,
MMCP-8, RMCP-8, and RMCP-9, will presumably be
Asp-speci¢c as well.
As with related serine proteases, the catalytic residues of
human granzyme B, His 57, Asp 102 and Ser 195, are
located at the junction of the two L-barrels with the active
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site cleft perpendicular to this junction. Similarly, the N-
terminal amino acid of the mature granzyme B, Ile 16, lies
in the interior of the molecule, where its ammonium group
forms an internal salt bridge with the side chain carbox-
ylate of Asp 194. This salt bridge formation is linked to
the creation of the oxyanion hole and the functional S1
pocket in the mature protease [26]. When the re¢ned gran-
zyme B and cathepsin G structures are aligned on 220
residues with similar secondary structure or conformation
(Fig. 1B), the average di¡erence between equivalent CK
atoms is 0.50 Aî (r.m.s. 0.40 Aî ). The poorly resolved
loop, composed of residues Asp 36A, Gln 36B, Lys 37
and Ser 38, was not included in the overall alignment since
the corresponding loop in cathepsin G has no electron
density [23]. The two insertions into the granzyme B se-
quence, Pro 145A and Arg 172A, determined by the align-
Table 1
Comparison of speci¢c residues of serine proteases with a Xaa 221^Xaa 224^Pro 225^Arg 226 motif
216 221 224 225 226 228 P1 speci¢city
Human granzyme B Gly Met Pro Pro Arg Cys Asp
Mouse granzyme B Gly Ser Pro Pro Arg Phe Asp
Rat granzyme B Gly Ser Thr Pro Arg Phe Asp
Rat granzyme J Arg Thr Pro Pro Arg Phe unknown
Rat mast cell protease-9 Arg Thr Pro Pro Arg Phe unknown
Rat mast cell protease-8 Arg Thr Leu Pro Arg Phe unknown
Mouse mast cell protease-8 Arg Thr Leu Pro Arg Phe unknown
Fig. 2. (A) Hydrogen bonds and other polar interactions between Ac-IEPD-CHO (Ki = 80 nM) and human granzyme B. Orange residues are the cata-
lytic triad, purple residues are protein, black residues are inhibitor. (B) Between Suc^Val^Pro^Phe(P)^(OPh)2 (irreversible transition state analogue in-
hibitor) and human cathepsin G [23]. (C) Between Ac-DEVD-CHO (Ki = 0.35 nM) and human caspase-3 [19]. (D) Between Ac-YVAD-CHO (Ki = 0.76
nM) and human caspase-1 [19].
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ment of the sequences and the structures, and the C-ter-
minal Tyr 245 for which no electron density is evident,
were also not included in the overall alignment. The 13
arginines and 19 lysines of granzyme B are solvent-ex-
posed except for Arg 226 in S1. These residues produce
large positively charged surface patches mostly distant
from the active site. Since there are only nine solvent-ex-
posed glutamate and seven solvent-exposed aspartate res-
idues, the resulting surface of the enzyme is relatively ba-
sic. Two additional aspartic acids, Asp 102, a member of
the catalytic triad, and Asp 194, salt-linked to Ile 16, are
not solvent-exposed.
Mass spectral analysis of human recombinant granzyme
B identi¢es one major peak at 27 466 Da (see Section 4).
Since the combined mass of the 227 amino acids de¢ned
by sequence analysis only accounts for 25 512 Da, gran-
zyme B has approximately two glycosylation sites account-
ing for the 1954 Da mass di¡erence. The electron density
clearly identi¢es two Asn-linked, solvent-exposed glycosyl-
ation sites extending from the side chains of Asn 65 and
Asn 98. Only the ¢rst N-acetyl glucosamine (GlcNAc) res-
idue of the N-linked carbohydrate is clearly visible o¡ of
Asn 65 while six residues (two GlcNAc, one fucose, three
mannose) of the complex N-linked glycans [30] are bound
to the side chain of Asn 98. These seven residues account
for 1312 Da. The electron density becomes very weak
beyond these residues because of crystallographic disorder.
Di¡erence density maps also identify ¢ve tetrahedrally co-
ordinated zinc ions. Zinc sulfate was used as an additive
during crystallization producing zinc ions as artifacts of
crystallization. Zinc is not required for substrate binding
(M. Garcia-Calvo, unpublished results). Four of the ¢ve
zinc ions are coordinated by at least one NO2 atom of the
imidazole ring of a histidine residue. The carboxylate oxy-
gens of aspartic and glutamic acids coordinate the ¢fth
zinc ion. Three of the ¢ve zinc ions are coordinated by
amino acid side chains from symmetry-related molecules
of granzyme B in complex with Ac-IEPD-CHO. The other
two ions are solvent-exposed. Four of the ¢ve zinc sites are
coordinated by at least one water molecule. The observed
tetrapeptide aldehyde inhibitor of granzyme B sits in the
active site groove on the highly charged surface of the
protein in an extended conformation, similar to the P1^
P4 residues of the inhibited caspase structures (see Fig. 4).
However, the hydrogen bonds and polar interactions in-
volving the aspartic acid at P1 are noticeably di¡erent in
granzyme B and caspase-3 (see Fig. 2). The well-de¢ned
and extensive granzyme B prime subsites, S1P^S3P, are also
considerably di¡erent from those in the caspases.
2.2. Speci¢city di¡erences at the S1 and S prime subsites
The tetrapeptide aldehyde inhibitor, Ac-Ile-Glu-Pro-
Asp-CHO, is bound in a groove in the enzyme surface
(see Fig. 4). The side chains at P1 and P4 project into
pronounced depressions in the binding groove where
they make numerous interactions with the protein while
the P2 and P3 side chains point away from the body of the
protein. The hydrogen bonds and other polar interactions
between the inhibitor and the protein are shown in Fig. 2.
As predicted [14,24], inhibited granzyme B, like cathepsin
G, caspase-3 and caspase-1, has three anti-parallel L-struc-
ture-like hydrogen bonds between the inhibitor backbone
and the enzyme (Fig. 2) : granzyme B and cathepsin G, P1
Fig. 3. Comparison of the S1 subsites. The surface of the protein is represented by mesh and the entry into the binding pocket is from the right of the
picture. (A) The aspartic acid side chain of Ac-IEPD-CHO bound to granzyme B includes three water molecules in the S1 subsite. (B) The P1 aspartic
acid side chain of Ac-DEVD-CHO bound to caspase-3.
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NTSer 214 O, P3 NTGly 216 O, and P3 OTGly 216 N;
caspase-3 and caspase-1, P1 NTSer 339 O, P3 NTArg 341
O, and P3 OTArg 341 N. However, there are no hydrogen
bonds involving the P2 and P4 carbonyls and the P4
amide of Ac-IEPD-CHO with granzyme B. The absence
of these bonds bene¢ts the development of future inhib-
itors by reducing the number of peptide-like features re-
quired for inhibition.
The S1 subsite of granzyme B di¡ers from the model of
cathepsin G used for molecular replacement. Cathepsin G
has a negatively charged glutamic acid in amino acid po-
sition 226 that is o¡ to one side of the S1 site, hydrogen-
bonded to the amide nitrogen and carbonyl of Ala 190.
The P1 speci¢city for cathepsin G is Phe. Granzyme B has
a positively charged arginine residue that results in a
change of both the size and chemical composition of the
S1 subsite. Arg 226 in granzyme B forms a partial base to
the site and allows an extensive network of waters to form
o¡ to one side of the P1 side chain (see Fig. 3). These
unique features make S1 Asp-speci¢c and also provide
the room necessary to build inhibitors with extensions
into this site for improved speci¢city. When granzyme B
and caspase-3 are compared, the amino acid compositions
of the corresponding subsites di¡er signi¢cantly in both
their overall geometry and their chemical nature. Gran-
zyme B and the caspases are the only known mammalian
proteases with a primary speci¢city for aspartic acid
[14,15]. All of the known caspase structures are virtually
identical at the S1 subsite suggesting identical modes of
substrate recognition and catalytic mechanism [17^22].
The ability of the negatively charged P1 aspartyl side
chain of inhibitors and substrates to stabilize the local
concentration of the two positive charges of the arginyl
side chains in the S1 subsite of these enzymes, is consistent
with the near absolute requirement for Asp in P1
[15,19,31]. Although granzyme B has the same primary
speci¢city, its Asp-speci¢c S1 subsite is signi¢cantly larger
(Fig. 3) and less charged than the corresponding conserved
site in the caspases. The granzyme B S1 subsite contains
only one positively charged group, Arg 226, in contrast to
the two arginine side chains present in the caspase-3 S1
subsite. These subsite di¡erences probably account for the
variation in orientation of the P1 aspartic acids in the
active sites (Fig. 5A). The P1 aspartic acid side chain of
Ac-IEPD-CHO interacts with the guanidinium group of
Arg 226 and also forms hydrogen bonds with an extended
network of three water molecules within the S1 subsite of
granzyme B.
An ‘oxyanion hole’, which is presumed to stabilize the
oxyanion of the reaction intermediates formed during cat-
alysis, is made by the amide nitrogen atoms of Gly 193,
Asp 194 and Ser 195. The a⁄nity of peptide aldehyde
inhibitors for serine proteases was initially attributed to
the ability of these compounds to form a hemiacetal
with the active site serine that resembles the transition
state in amide bond hydrolysis, with the oxyanion stabi-
lized in the oxyanion hole. In the granzyme B^Ac-IEPD-
CHO complex, the aldehyde carbonyl of the P1 aspartic
acid forms a hemiacetal with the Q oxygen of the active site
Ser 195 of granzyme B (Fig. 5C). The inhibitor of gran-
zyme B appears to bind predominantly in the transition
state conformation, with the oxyanion of the hemiacetal
stabilized by hydrogen bonds to the amide nitrogens of
Gly 193, Asp 194 and Ser 195 but there are indications
of disorder. In the alternate conformation, the oxyanion
forms a hydrogen bond with the amide nitrogen of Gly
193. Carefully designed re¢nement experiments on this
complex failed to establish de¢nitively either the transition
Fig. 4. Comparison of the active sites surfaces of (A) granzyme B (blue represents positive charge; and the red, negative) with Ac-IEPD-CHO (atom
color ball-and-stick model) and (B) caspase-3 with Ac-DEVD-CHO. The respective protein complexes were aligned on the four residue CK’s of the in-
hibitors, producing the average di¡erence between equivalent CK atoms of 0.38 Aî (r.m.s. 0.12 Aî ). 375 Aî 2 of the surface of granzyme B is buried by the
inhibitor Ac-IEPD-CHO while 348 Aî 2 of the surface of caspase-3 is buried by the inhibitor Ac-DEVD-CHO.
CHBIOL 83 18-4-01 Cyaan Magenta Geel Zwart
362 Chemistry & Biology 8/4 (2001) 357^368
or non-transition state conformation to the exclusion of
the other. In parallel re¢nements, each conformation ¢tted
equally well to electron density maps and to simulated
annealing omit maps. Di¡erence electron density maps
based on each conformation contained indications sug-
gesting some contribution from the alternate conforma-
tion. Disordered binding of peptide aldehyde inhibitors
has been observed in some serine proteases, suggesting
that this mode of binding may be of some generality
[32,33]. Similar experiments [19] on a cysteine protease,
caspase-3, also demonstrate disorder in the binding of an
inhibitor. Recently, the 1.2 Aî structure of human caspase-
8 in complex with Ac-IETD-CHO clearly shows that the
thiohemiacetal binds in a non-transition state conforma-
tion [20].
Combinatorial synthetic substrate libraries and sub-
strate phage display showed the optimal substrate se-
quence for granzyme B, spanning six subsites, P4^P2P, to
be (P4)Ile^Glu^Xaa^AspsXaa^Gly(P2P) with the cleavage
at the AspsXaa peptide bond [14]. The de¢nitions of the
S1P, S2P, and S3P subsites in granzyme B are consistent
with data demonstrating that the enzyme^substrate inter-
actions C-terminal to the scissile bond are catalytically
signi¢cant and play a role in determining substrate specif-
icity [14]. Caspase-3 has an extended shallow groove on
the surface of the protein representing the S1P subsite
while granzyme B has deep, tunnel-like features de¢ning
S1P, S2P, and S3P subsites. In granzyme B, S1P is a large
hydrophobic pocket formed by the disul¢de bridge be-
tween Cys 58 and Cys 42, the carbon atoms of the side
chain of Lys 40, and the side chain of Ile 35. This pocket is
large enough to ¢t a tryptophan. The prime subsites con-
tinue with a narrow corridor, representing S2P, to another
network of waters forming the hydrophilic S3P subsite
(Fig. 5D). This narrow corridor, between the side chain
of Arg 41, the main chain of Gly 193, and the side chain
of His 151 is consistent with the speci¢city for glycine at
P2P. Our structure of granzyme B has identi¢ed a large
hydrophilic S3P subsite formed by the main chain atoms
between Arg 41 and Gly 43, Val 138 and Gly 142, and Gly
193 and Pro 198 and covered by the side chains of Tyr 32,
Trp 141 and Met 30. This ‘subsite’ is ¢lled with four well-
de¢ned water molecules and may actually be more than
one subsite.
2.3. Other interactions with inhibitor
The S4 subsite of granzyme B is a shallow hydrophobic
depression formed by aromatic rings (Tyr 174 and Tyr
215) and the side chain of Leu 172. However, the surface
edges of the S4 subsite are composed of solvent-exposed
arginines (Arg 217 and Arg 172A). Our structure, with an
Ile in P4, and the P4 peptide speci¢city pro¢le [15] dem-
onstrates that there is not enough room for a P4 phenyl-
alanine. In contrast, the S4 subsite of caspase-3 is a nar-
row pocket that closely envelops the P4 Asp side chain.
This pocket is sterically constricted by the side chains of
Trp 348 and Phe 381B and the required P4 aspartic acid
makes speci¢c polar interactions with Phe 381A and Asn
342 (which extends its hydrogen bond network by addi-
tional polar interactions with the amide nitrogens of Ser
343, Lys 344 and Asp 345). Thus, the S4 subsite of gran-
zyme B is less constricted and more hydrophobic than the
corresponding subsite in caspase-3.
The side chains of the preferred P3 glutamic acid resi-
dues in both granzyme B and caspase-3 point away from
the body of the protein. The P3 amide nitrogen and car-
bonyl of these proteins form anti-parallel L-structure-like
hydrogen bonds with the main chain of their respective
protein. The side chain of P3 Glu of granzyme B interacts
with both Asn 218 and Lys 192, stabilizing the lysine side
chain along the edge of the groove of the binding site.
Similarly, P3 Glu in caspase-3 makes a salt link to the
side chain of Arg 341 and a polar interaction with the
side chain of Ser 343, consistent with the speci¢city of
the enzyme at this site.
In the caspase-3^Ac-DEVD-CHO complex, the side
chain of the P2 valine points away from the body of the
protein and lies against a hydrophobic wall of the groove
and adjacent to the side chain of Tyr 338. In granzyme B,
the aromatic ring of Phe 99 forms a hydrophobic wall at
the S2 subsite and the catalytic His 57 is £ipped up (M1
rotation), out of its catalytic formation with Ser 195 and
Asp 102, adapting an conformation previously observed in
other serine protease structures [34]. In granzyme B, the
P2 proline points away from the body of the protein and
makes no speci¢c interactions with the protein. Just be-
yond the pentameric pyrrolidine ring of the proline, there
is a pocket formed by the side chains of Phe 99, Tyr 94,
Asp 102, His 57 and the main chain of Pro 96. Extensions
to this ring may improve binding to granzyme B. This
proline induces a slight kink in the tetrapeptide inhibitor
of granzyme B allowing the P1 aspartic acid to reach its
optimal conformation in the S1 subsite (Fig. 5A)
[23,25,35].
2.4. Comparison of the structures of human and rat
granzyme B
The recently published structure of the complex between
rat granzyme B and the macromolecular inhibitor ecotin
[29] is quite similar to the present structure in its overall
features. When the structures are aligned, the r.m.s. devi-
ation between 217 structurally related K-carbon atoms is
0.59 Aî . There are a few di¡erences in the composition of
speci¢c subsites because of sequence di¡erences between
the human and rat proteins. In S2, Phe 99 of human
granzyme B is an isoleucine in rat. In S2P, His 151 is a
tyrosine in rat while Arg 41 is a lysine. The di¡erences in
S1 are particularly striking. Cys 228 of human granzyme B
is a phenylalanine in the rat enzyme (Table 1). This change
results in a signi¢cantly larger S1 subsite in the human
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protein. While this site is a narrow pit, approximately 7 Aî
in diameter and 9 Aî deep in the rat enzyme, the Phe^Cys
sequence di¡erence results in an extra channel in the hu-
man S1, extending towards Val 138 and approximately 7 Aî
in length. This added volume contains three ordered water
molecules in the human enzyme. Also, the speci¢c polar
interactions between the Asp side chain of the substrate/
inhibitor and Arg 226 di¡er in detail. In the human com-
plex, there is a single interaction between ON2 of the P1
aspartic acid and NR2 of Arg 226, while in the rat com-
plex there is a bidentate interaction involving both ON’s of
the P1 Asp and the NO and NR2 atoms of Arg 226. These
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di¡erences may arise both from speci¢c sequence di¡er-
ences between the rat and human enzymes as well as the
fact that rat granzyme B is in complex with a cleaved
substrate, while human granzyme B is inhibited by a tet-
rapeptide aldehyde. The S1 subsite di¡erences between rat
and human granzyme B will a¡ect the binding of non-
peptidyl inhibitors. Phe 228, which points directly into
S1, is found in rat and mouse granzyme B, MMCP-8,
RMCP-8, and RMCP-9 (Table 1). Only human granzyme
B has an extended S1 subsite with three water molecules
and a cysteine at residue 228. Thus, a speci¢c inhibitor’s
structure activity relationship with rat granzyme B may
not be predictive of its ability to inhibit human granzyme
B.
3. Signi¢cance
The three-dimensional structure of granzyme B is gen-
erally similar in secondary and tertiary structure to that of
trypsin-like serine proteases. Despite this super¢cial simi-
larity, there are profound di¡erences in the S1 subsite that
account for the distinct macromolecular speci¢cities and
di¡erent biological functions of these enzymes. The strict
requirement for aspartic acid in the P1 position of sub-
strates and inhibitors of granzyme B, a speci¢city not pre-
viously seen in serine proteases, is con¢rmed by the geom-
etry and the chemical nature of this subsite. In addition,
the results presented here provide a structural basis for the
design of highly speci¢c inhibitors of human granzyme B.
The absence of hydrogen bonds involving the P2 and P4
carbonyls and the P4 amide eliminates the number of pep-
tide bonds necessary to build this inhibitor. The extensions
possible from P2 and/or into S1 as well as the SP subsites
should improve our inhibitors and aid in the identi¢cation
of the appropriate targets for therapeutic intervention.
4. Materials and methods
4.1. Granzyme B production
Plasmid pMelBac and the TA cloning kit (pCR2.1) were pur-
chased from Invitrogen (Carlsbad, CA, USA). The Bac-to-Bac
baculovirus expression system and all cell culture supplies were
from Life Technologies (Gaithersburg, MD, USA). The full
length human granzyme B clone was a generous gift from Dr.
Chris Bleakley [36]. A vector was generated for secreted protein
expression in the Bac-to-Bac system. The honeybee melittin se-
cretion signal was ampli¢ed from pMelBac by PCR with primers
5P-GTGT AGA TCT ATG AAA TTC TTA GTC AAC G-3P and
5P-TTC AGC AGA GTC GAC TCC AAG-3P. The ampli¢ed
product contained a BglII site upstream of the melittin secretion
signal and spanned the multiple cloning site of the vector. The
fragment was digested with BglII and EcoRI and subcloned into
BamHI and EcoRI digested pFastBac. The resulting vector was
designated pSecBac. Tagged human granzyme B was cloned into
pSecBac in two sequential steps. Firstly, mature granzyme B was
ampli¢ed from Dr. Bleakley’s clone by PCR with primers 5P-
GGATCC ATC GAA GGT CGT ATC ATC GGAGGACAT-
GAGGCC-3P and 5P-AAG CTT TTA GTA GCG CTT CAT
GGT CTT CTT TAT CC-3P and cloned into pCR2.1. In the
sense primer, the bold type sequence coding for the factor Xa
recognition site, Ile^Glu^Gly^Arg, was inserted upstream of iso-
leucine 21 (referred to as Ile 16 in this paper using the numbering
scheme for this family of serine proteases that is traditionally
based on the zymogen, chymotrypsinogen), the ¢rst amino acid
of mature granzyme B. Secondly, hexa-histidine tagged granzyme
B was ampli¢ed from the granzyme B/pCR2.1 clone by PCR
using primers 5P-GGA AGA TCT CAT CAT CAT CAT CAT
CAT GGA TCC ATC GAA GGT CGT ATC-3P and 5P-CCT
GAA TTC TTA GTA GCG TTT CAT GGT CTT CTT TAT
CC-3P. The ampli¢ed product contained a BglII site upstream of
the hexa-histidine tag and contained the factor Xa recognition
sequence. This fragment was digested with BglII and EcoRI
and subcloned into BamHI and EcoRI digested pSecBac. The
completed vector generated a recombinant baculovirus in Gibco
BRL’s Bac-to-Bac system, which would produce a secreted,
6-histidine tagged granzyme B. For protein expression, sf9 cells
were grown to a density of 1.5U106 cells ml31 in Grace’s medium
(Cat. 11605-094) supplemented with 10% fetal calf serum and
penicillin^streptomycin^glutamine (Cat. 10378-024). Prior to the
addition of virus, cells were centrifuged at 1000Ug for 15 min
and resuspended to the same density in fresh growth medium
containing recombinant viral stock and SP Sepharose beads
(4 ml resin per liter of culture). After 72 h of induction at 27‡C,
the resin was collected in a 50 W nylon mesh (PGC Scienti¢cs), ex-
tensively washed with 50 mM MES^NaOH, 0.3 M NaCl, pH 6.6
Fig. 5. (A) Stereoview of overlay of the bound conformation of Ac-IEPD-CHO (atom color ball-and-stick model) from the granzyme B complex and
Ac-DEVD-CHO (silver ball-and-stick model) from the caspase-3 complex. The respective inhibitors were aligned as in Fig. 4. (B) Electron density in
the region of the bound inhibitor. (2Fo3Fc) electron density map calculated with the ¢nal re¢ned phases is superimposed on the re¢ned model. (C) The
S1 subsite. The carbonyl of P1 forms a hemiacetal with the Q oxygen of the active site Ser 195. The P1 aspartic acid side chain interacts with the main
chain amide nitrogen of Lys 192 and the guanidinium group of Arg 226 (that also forms the base of S1). There is an extended network of three water
molecules in S1. (The terminal side chain nitrogen of Lys 192 is H-bonded to the P3 glutamic acid side chain.) S1 contains only one positively charged
group, in contrast to the two arginine side chains in the caspase S1 subsites. (D) The prime subsites of granzyme B. The granzyme B surface is repre-
sented by the silver mesh. S1P is a large hydrophobic pocket adjacent to a relatively small S2P and a large S3P which is ¢lled with another network of
water molecules. S1P is a large hydrophobic pocket formed by a disul¢de bridge (Cys 42^Cys 58), the carbon atoms of the side chain of Lys 40 and the
side chain of Ile 35. This prime site continues with a narrow corridor (formed by Arg 41 and His 151) to another network of waters forming the hydro-
philic S3P subsite (follow the four waters in the prime subsites from right to left).
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and poured into a column. The protein was eluted using a linear
gradient (0.3^1.0 M) of NaCl. Since the eluted granzyme B is
inactive, aliquots of the fractions were incubated overnight with
factor Xa and the activity of the resulting granzyme B was mea-
sured in a continuous £uorometric assay using Ac-IETD-AMC as
a substrate, similar to the previously described assays for the
caspases [37^39]. Fractions containing granzyme B activity were
identi¢ed, combined and concentrated and then diluted in 20 mM
Tris^HCl, pH 8.0. The sample was readjusted to a ¢nal pH 8.0,
CaCl2 (3 mM ¢nal concentration) and factor Xa (Pharmacia, 10
units per mg of protein) was added, and incubated for 18 h at
room temperature to generate active granzyme B. Under these
conditions, complete cleavage is achieved. The recombinant gran-
zyme B was puri¢ed from the cleavage mixture using a 1 ml
HiTrap SP column (Pharmacia). The yield can be as much as
4^5 mg of active, puri¢ed granzyme B per liter of culture as
measured using the above £uorometric assay. Mass spectral anal-
ysis identi¢es one major peak at 27 466 Da (other components of
27 320 Da and 26 630 Da were also consistently observed). Since
the combined mass of the 227 amino acids de¢ned by sequence
analysis only accounts for 25 511.58 Da, we concluded that prep-
arations of recombinant granzyme B puri¢ed with this method
are more homogeneous and less glycosylated than preparations of
native granzyme B puri¢ed from NK cell granules (data not
shown). Nevertheless, the resulting enzyme is indistinguishable
from native enzyme with regard to kinetic parameters for inhibi-
tion by Ac-IEPD-CHO and other inhibitors.
4.2. Crystallization, data measurement, structure solution
The granzyme B^Ac-IEPD-CHO complex was crystallized by
hanging-drop vapor di¡usion. 0.5 ul drops of protein^inhibitor
solution (12.2 mg ml31 in 20 mM Tris^HCl pH 8.0, 200 mM
NaCl) were mixed with an equal volume of precipitant solution
(25% PEG monomethyl ether-550 (v/v), 0.10 M MES pH 6.5, 10
mM ZnSO4, 12 mM ZnCl2) and incubated at room temperature
over a reservoir of 24% w/v PEG-3350, 12.8% v/v PEG MME-
550, 50 mM MES pH 6.5, 5 mM ZnSO4, and 6 mM ZnCl2. The
crystals belong to the orthorhombic space group P212121 with
a = 48.87, b = 75.08, c = 80.26 Aî . Three-dimensional di¡raction
data extending to a resolution of 2.0 Aî were collected at beamline
17-ID in the IMCA-CAT facilities at the Advanced Photon
Source (see acknowledgments) using monochromatic wavelength
of 1.0 Aî and a 165 mm Mar Research CCD image plate detector.
These data were processed with the HKL2000 software package
[40]. 163 991 observations of 19 956 unique re£ections were
merged with an R-factor of 4.4%. The structure was solved by
molecular replacement, using X-PLOR [41] and a model based on
cathepsin G [23] (Protein Data Bank [42] entry 1CGH). The
current model was constructed by interactive model building
[43^45] and re¢ned with X-PLOR and CNX [46] using all dif-
fraction data. The current model was inspected against simulated
annealing omit maps [47] and comprises residues 16^244 of the
protein, the bound inhibitor, 114 ordered water molecules, ¢ve
zinc ions and a total of seven residues of the complex N-linked
glycans are bound to the side chains of Asn 65 and Asn 98. The
electron density becomes very weak beyond these residues be-
cause of crystallographic disorder. The R-factor of the re¢ned
model is 24.7% (Rfree = 27.5%) [48] and the stereochemistry is rea-
sonable (r.m.s. deviation of bonds = 0.009 Aî , angles = 1.54‡).
Crystallographic statistics are presented in Table 2. The R-factor
of the ¢nal model is most likely a¡ected by the disorder present in
the glycosylation sites. Over 600 Da of the glycosylated granzyme
B complex are not capable of being modeled. Subsequent re¢ne-
ments of other inhibited granzyme B complexes (data not shown)
have extended to a resolution of 1.8 Aî thus increasing the number
of visible carbohydrate residues and decreasing the R-factor sig-
ni¢cantly. Secondary structures were assigned to granzyme B us-
ing the program STRIDE [48]. Special care was taken to establish
the chirality at the optical center created by the nucleophilic
attack of Ser 195 OH at the P1 carbon atom. After re¢nement
was completed, equivalent models were constructed for each pos-
sible con¢guration at this atom and the two models were re¢ned
in parallel with chiral restraints that were identical in magnitude,
but opposite in hand. Then, all atoms within 8.0 Aî of this atom
were deleted from each model and both truncated models were
subjected to a 2000 K simulated annealing re¢nement. Electron
density maps and simulated annealing omit electron density maps
of this part of the complex were then calculated from both sets of
phases and inspected to determine the stereochemistry at this site.
The coordinates and structure factors of the granzyme B^Ac-
IEPD-CHO complex have been deposited in the Protein Data
Bank [42] and the PDB code is 1IAU.
Acknowledgements
We thank Dr. R. Chris Bleackley (Department of Bio-
chemistry, University of Alberta, Edmonton, AB, Canada)
for the full length human granzyme B clone. We are grate-
Table 2
Crystallographic data and re¢nement
Crystals Data collection Re¢nement
Space group P212121 Re£ections R.m.s. deviation
Unit cell a = 48.87 Aî observed 163 991 of bonds 0.009 Aî
b = 75.08 Aî unique 19 956 of angles 1.539‡
c = 80.26 Aî completeness 95% to 2.0 Aî
Rfree 27.5%
Resolution 2.0 Aî Rmerge 4.4% R 24.7%
CHBIOL 83 18-4-01 Cyaan Magenta Geel Zwart
366 Chemistry & Biology 8/4 (2001) 357^368
ful for the advice and expertise of Dr. Antony Rosen
(Johns Hopkins University School of Medicine, Baltimore,
MD, USA).
Data were collected at beamline 17-ID in the facilities of
the Industrial Macromolecular Crystallography Associa-
tion Collaborative Access Team (IMCA-CAT) at the Ad-
vanced Photon Source. These facilities are supported by
the companies of the Industrial Macromolecular Crystal-
lography Association through a contract with Illinois In-
stitute of Technology (IIT), executed through the IIT’s
Center for Synchrotron Radiation Research and Instru-
mentation. Use of the Advanced Photon Source was sup-
ported by the U.S. Department of Energy, Basic Energy
Sciences, O⁄ce of Science, under contract no. W-31-109-
Eng-38. We sincerely appreciate the assistance of the
IMCA sta¡.
References
[1] E.A. Atkinson, R.C. Bleackley, Mechanisms of lysis by cytotoxic T
cells, Crit. Rev. Immunol. 15 (1995) 359^384.
[2] G. Berke, The CTL’s kiss of death, Cell 81 (1995) 9^12.
[3] P.A. Henkart, Lymphocyte-mediated cytotoxicity: two pathways and
multiple e¡ector molecules, Immunity 1 (1994) 343^346.
[4] J.W. Heusel, R. Wesselschmidt, S. Shresta, J. Russell, T.J. Ley, Cy-
totoxic lymphocytes require granzyme B for rapid induction of DNA
fragmentation and apoptosis in allogeneic target cells, Cell 76 (1994)
977^984.
[5] L. Shi, R.P. Kraut, R. Aebersold, A.H. Greenberg, A natural killer
cell granule protein that induces DNA fragmentation and apoptosis,
J. Exp. Med. 175 (1992) 553^566.
[6] M. Poe, J.T. Blake, D.A. Boulton, M. Gammon, N.H. Sigal, J.K.
Wu, H.J. Zweerink, Human cytotoxic lymphocyte granzyme B. Its
puri¢cation from granules and the characterization of substrate and
inhibitor speci¢city, J. Biol. Chem. 266 (1991) 98^103.
[7] M.C. Peitsch, J. Tschopp, Granzyme B, Methods Enzymol. 244
(1994) 80^87.
[8] A.J. Darmon, D.W. Nicholson, R.C. Bleackley, Activation of the
apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B,
Nature 377 (1995) 446^448.
[9] S.J. Martin, G.P. Amarante-Mendes, L. Shi, T.-H. Chuang, C.A.
Casiano, G.A. O’Brien, P. Fitzgerald, E.M. Tan, G.M. Bokoch,
A.H. Greenberg, D.R. Green, The cytotoxic cell protease granzyme
B initiates apoptosis in a cell-free system by proteolytic processing
and activation of the ICE/CED-3 family protease, CPP32, via a novel
two-stop mechanism, EMBO J. 15 (1996) 2407^2416.
[10] A. Sarin, M.S. Williams, M.A. Alexander-Miller, J.A. Berzofsky,
C.M. Zacharchuk, P.A. Henkart, Target cell lysis by CTL granule
exocytosis is independent of ICE/Ced-3 family proteases, Immunity 6
(1997) 209^215.
[11] F. Andrade, S. Roy, D.W. Nicholson, N.A. Thornberry, A. Rosen,
L. Casciola-Rosen, Granzyme B directly and e⁄ciently cleaves sev-
eral downstream caspase substrates : implications for CTL-induced
apoptosis, Immunity 8 (1998) 451^460.
[12] D.A. Thomas, C. Du, M. Xu, X. Wang, T.J. Ley, DFF45/ICAD can
be directly processed by granzyme B during the induction of apopto-
sis, Immunity 12 (2000) 621^632.
[13] N.A. Thornberry, S.M. Molineaux, Interleukin-1L converting en-
zyme: a novel cysteine protease required for IL-1L production and
implicated in programmed cell death, Protein Sci. 4 (1995) 3^12.
[14] J.L. Harris, E.P. Peterson, D. Hudig, N.A. Thornberry, C.S. Craik,
De¢nition and redesign of the extended substrate speci¢city of gran-
zyme B, J. Biol. Chem. 273 (1998) 27364^27373.
[15] N.A. Thornberry, T.A. Rano, E.P. Peterson, D.M. Rasper, T. Tim-
key, M. Garcia-Calvo, V.M. Houtzager, P.A. Nordstrom, S. Roy,
J.P. Vaillancourt, K.T. Chapman, D.W. Nicholson, A combinatorial
approach de¢nes speci¢cities of members of the caspase family and
granzyme B, J. Biol. Chem. 272 (1997) 17907^17911.
[16] L. Casciola-Rosen, F. Andrade, D. Ulanet, W.B. Wong, A. Rosen,
Cleavage by granzyme B is strongly predictive of autoantigen status:
implications for initiation of autoimmunity, J. Exp. Med. 190 (1999)
815^825.
[17] K.P. Wilson, J.A. Black, J.A. Thomson, E.E. Kim, J.P. Gri⁄th,
M.A. Navia, M.A. Murcko, S.P. Chambers, R.A. Aldape, S.A. Ray-
buck, Structure and mechanism of interleukin-1 beta converting en-
zyme, Nature 370 (1994) 270^275.
[18] N.P. Walker, R.V. Talanian, K.D. Brady, L.C. Dang, N.J. Bump,
C.R. Ferenz, S. Franklin, T. Ghayur, M.C. Hackett, L.D. Hammill,
Crystal structure of the cysteine protease interleukin-1 beta-convert-
ing enzyme: a (p20/p10)2 homodimer, Cell 78 (1994) 343^352.
[19] J. Rotonda, D.W. Nicholson, K.M. Fazil, M. Gallant, Y. Gareau,
M. Labelle, E.P. Peterson, D.M. Rasper, R. Ruel, J.P. Vaillancourt,
N.A. Thornberry, J.W. Becker, The three-dimensional structure of
apopain/CPP32, a key mediator of apoptosis, Nat. Struct. Biol. 3
(1996) 619^625.
[20] W. Watt, K.A. Koeplinger, A.M. Mildner, R.L. Heinrikson, A.G.
Tomasselli, K.D. Watenpaugh, The atomic-resolution structure of
human caspase-8, a key activator of apoptosis, Struct. Fold. Des. 7
(1999) 1135^1143.
[21] H. Blanchard, L. Kodandapani, P.R. Mittl, S.D. Marco, J.F. Krebs,
J.C. Wu, K.J. Tomaselli, M.G. Grutter, The three-dimensional struc-
ture of caspase-8: an initiator enzyme in apoptosis, Struct. Fold. Des.
7 (1999) 1125^1133.
[22] Y. Wei, T. Fox, S.P. Chambers, J. Sintchak, J.T. Coll, J.M.C. Golec,
L. Swenson, K.P. Wilson, P.S. Charifson, The structures of caspases-
1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity,
Chem. Biol. 7 (2000) 423^432.
[23] P. Hof, I. Mayr, R. Huber, E. Korzus, J. Potempa, J. Travis, J.C.
Powers, W. Bode, The 1.8 Ang crystal structure of human cathepsin
G in complex with Suc-Val-Pro-Phe(P)-(OPh)2: a Janus-faced pro-
teinase with two opposite speci¢cities, EMBO J. 15 (1996) 5481^5491.
[24] M.E.P. Murphy, J. Moult, R.C. Bleackley, H. Gershenfeld, I.L.
Weissman, M.N.G. James, Comparative molecular model building
of two serine proteinases from cytotoxic T lymphocytes, Proteins
Struct. Funct. Genet. 4 (1988) 190^204.
[25] P.J.B. Pereira, Z.-M. Wang, H. Rubin, R. Huber, W. Bode, N.M.
Schechter, S. Strobl, The 2.2 Ang crystal structure of human chymase
in complex with succinyl-Ala-Ala-Pro-Phe-chloromethylketone:
structural explanation for its dipeptidyl carboxypeptidase speci¢city,
J. Mol. Biol. 286 (1999) 163^173.
[26] W. Bode, R. Huber, Structural basis of the endoproteinase^protein
inhibitor interaction, Biochim. Biophys. Acta 1477 (2000) 241^252.
[27] S.J. Remington, R.G. Woodbury, R.A. Reynolds, B.W. Matthews,
H. Neurath, The structure of rat mast cell protease II at 1.9-A res-
olution, Biochemistry 27 (1988) 8097^8105.
[28] C. Lutzelschwab, G. Pejler, M. Aveskogh, L. Hellman, Secretory
granule proteases in rat mast cells. Cloning of 10 di¡erent serine
proteases and a carboxypeptidase A from various rat mast cell pop-
ulations, J. Exp. Med. 185 (1997) 13^29.
[29] S.M. Waugh, J.L. Harris, R.J. Fletterick, C.S. Craik, The structure of
the pro-apoptotic protease granzyme B reveals the molecular deter-
minants of its speci¢city, Nat. Struct. Biol. 7 (2000) 762^765.
[30] D.L. Jarvis, Z.S. Kawar, J.R. Hollister, Engineering N-glycosylation
pathways in the baculovirus-insect cell system, Curr. Opin. Biotech-
nol. 9 (1998) 528^533.
[31] N.A. Thornberry, Y. Lazebnik, Caspases: enemies within, Science
281 (1998) 1312^1316.
[32] L.T. Delbaere, G.D. Brayer, The 1.8 Ang structure of the complex
CHBIOL 83 18-4-01 Cyaan Magenta Geel Zwart
Research Paper Structure of granzyme B J. Rotonda et al. 367
between chymostatin and Streptomyces griseus protease A. A model
for serine protease catalytic tetrahedral intermediates, J. Mol. Biol.
183 (1985) 89^103.
[33] C. Ortiz, C. Tellier, H. Williams, N.J. Stolowich, A.I. Scott, Diaster-
otopic covalent binding of the natural inhibitor leupeptin to trypsin:
detection of two interconverting hemiacetals by solution and solid-
state NMR spectroscopy, Biochemistry 30 (1991) 10026^10034.
[34] I. Botos, E. Meyer, M. Nguyen, S.M. Swanson, J.M. Koomen, D.H.
Russell, E.F. Meyer, The structure of an insect chymotrypsin, J. Mol.
Biol. 298 (2000) 895^901.
[35] S. Rehault, M. Brillard-Bourdet, M.A. Juliano, L. Juliano, F. Gauth-
ier, T. Moreau, New, sensitive £uorogenic substrates for human ca-
thepsin G based on the sequence of serpin-reactive site loops, J. Biol.
Chem. 274 (1999) 13810^13817.
[36] C.G. Lobe, B.B. Finlay, W. Paranchych, V.H. Paetkau, R.C. Bleack-
ley, Novel serine proteases encoded by two cytotoxic T lymphocyte-
speci¢c genes, Science 232 (1986) 858^861.
[37] N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D.
Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner,
J. Aunins, K.O. Elliston, J.M. Ayala, F.J. Casano, J. Chin, G.J.-F.
Ding, L.A. Egger, E.P. Ga¡ney, G. Limjuco, O.C. Palyha, S.M.
Raju, A.M. Rolando, J.P. Salley, T.-T. Yamin, T.D. Lee, J.E.
Shively, M. MacCoss, R.A. Mumford, J.A. Schmidt, M.J. Tocci, A
novel heterodimeric cysteine protease is required for interleukin-1-
beta processing in monocytes, Nature 357 (1992) 768^774.
[38] D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K.
Ding, M. Gallant, Y. Gareau, P.R. Gri⁄n, M. Labelle, Y. Lazebnik,
Identi¢cation and inhibition of the ICE/CED-3 protease necessary for
mammalian apoptosis, Nature 376 (1995) 37^43.
[39] M. Garcia-Calvo, E.P. Peterson, D.M. Rasper, J.P. Vaillancourt, R.
Zamboni, D.W. Nicholson, N.A. Thornberry, Puri¢cation and cata-
lytic properties of human caspase family members, Cell Death Di¡er.
6 (1999) 362^369.
[40] Z. Otwinowski, W. Minor, Processing of X-Ray Di¡raction Data
Collected in Oscillation Mode, Academic Press, New York, 1996.
[41] A.T. Brunger, X-PLOR: Version 3.1, a System for X-Ray Crystal-
lography and NMR, Yale University Press, New Haven, CT, 1992.
[42] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H.
Weissig, I.N. Shindyalov, P.E. Bourne, The Protein Data Bank, Nu-
cleic Acids Res. 28 (2000) 235^242.
[43] J.S. Sack, CHAIN - a crystallographic modeling program, J. Mol.
Graph. 6 (1988) 224^225.
[44] T.A. Jones, J.Y. Zou, S.W. Cowan, M. Kjeldgarrd, Improved meth-
ods for binding protein models in electron density maps and the
location of errors in these models, Acta Crystallograph. D 47
(1991) 110^119.
[45] G.J. Kleywegt, T.A. Jones, Software for handling macromolecular
envelopes, Acta Crystallograph. D 55 (1999) 941^944.
[46] A.T. Brunger, P.D. Adams, G.M. Clore, W.L. DeLano, P. Gros,
R.W. Grosse-Kunstleve, J.-S. Jiang, J. Kuszewski, M. Nilges, N.S.
Pannu, R.J. Read, L.M. Rice, T. Simonson, G.L. Warren, Crystal-
lography and NMR System: a new software suite for macromolecu-
lar structure determination, Acta Crystallograph. D 54 (1998) 905^
921.
[47] A. Hodel, S.-H. Kim, A.T. Brunger, Model bias in macromolecular
crystal structures, Acta Crystallograph. A 48 (1992) 851^858.
[48] D. Frishman, P. Argos, Knowledge-based protein secondary struc-
ture assignment, Proteins Struct. Funct. Genet. 23 (1995) 566^579.
CHBIOL 83 18-4-01 Cyaan Magenta Geel Zwart
368 Chemistry & Biology 8/4 (2001) 357^368
